Clinical Trials

Sponsor: AbbVie, Inc

Sponsor Study ID: M16-109

Study Title: A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis

NCT Number: NCT03222609

Phase: II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Other Hematopoietic

Study Objectives: This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.